A blood protein panel tied to menopause predicted faster brain aging and higher Alzheimer's risk across four independent cohorts of older women
A blood protein panel tied to menopause predicted faster brain aging and higher Alzheimer's risk across four independent cohorts of older women
Researchers at the Universities of California, Toronto, and Stanford precisely staged menopause in 80 women, compared their blood with that of 36 age-matched men, and then validated the finding in 2,814 women from the UK Biobank.
Among Americans over 65 with Alzheimer's disease, nearly two thirds are women: 4.5 of 7.4 million, according to the Alzheimer's Association. The disparity has been attributed to women's longer lifespan or to the vague phrase "hormones." A paper published on September 22 in Nature Medicine offers a concrete lead: a set of blood proteins that marks menopause separately from aging and is associated with future dementia risk.
In 80 women aged 43 to 58 and 36 men of the same age, serving as controls for ordinary aging, the authors measured 118 nervous system proteins. After adjusting for age, 16 of these were markedly elevated specifically in postmenopausal women. Some are involved in inflammation, some in synaptic function, and some are linked directly to Alzheimer's: the enzyme BACE1, which produces the toxic beta-amyloid peptide that accumulates in the brain in this disease, and phosphorylated tau231, an early marker of the tau protein damage from which characteristic tangles form inside neurons.
Combining these 16 proteins into a single "menopausal proteomic score," the authors compared it with age and with hormone levels. In men the score did not increase with age at all. In women, once menopausal stage was accounted for, the association with age disappeared, meaning the score reflects the hormonal transition rather than aging itself. The strongest correlate of the score was follicle-stimulating hormone (FSH), which rises sharply when the ovaries stop responding to signals from the pituitary, a gland at the base of the brain that controls their activity. BACE1 and two synaptic proteins correlated more tightly with FSH than with estrogen, and FSH receptors are present directly in brain regions vulnerable to Alzheimer's. In animal models, FSH itself triggers amyloid deposition and memory loss.
In the Biobank the authors replicated the shift for 9 of the 13 comparable proteins using a different proteomic platform. Hot flashes and night sweats, the most common symptoms of menopause, were both associated with the same inflammatory protein, CCL2, but at different ages: between 40 and 50, night sweats drove its elevation, while decades later hot flashes did so. The paper links this persistent inflammatory trace to brain risk.
The central test was carried out in four groups of women aged 61 to 72. A higher menopausal proteomic score was associated with faster cognitive decline in two of the groups and with lower memory test scores in a third. In the fourth, a separate, larger UK Biobank sample (11,059 women, 15.7 years of follow-up), the same score was associated with a 15% increase in risk specifically of Alzheimer's disease, not other forms of dementia. MRI scans of 843 women from the same Biobank do not find accelerated cortical thinning at the menopausal transition, suggesting the protein signal precedes structural brain changes.
The association between the proteins and cognition replicated across four cohorts and two measurement technologies, but dementia does not develop in most women who go through menopause. The authors themselves describe the boundary of the finding this way:
"The menopausal transition may be a vulnerable window for understanding and detecting the earliest signals of future brain aging risk."
If the link between FSH and the amyloid pathway is confirmed, neurologists would gain a measurable target for intervention decades before Alzheimer's symptoms appear.